OTCM
APLIF
Market cap930kUSD
Oct 06, Last price
0.00USD
1D
0.00%
IPO
-99.69%
Name
Appili Therapeutics Inc
Chart & performance
P/E
—
P/S
3.16
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.89%
Rev. gr., 5y
-12.79%
Revenues
244k
+143.10%
Net income
-4m
L+61.57%
CFO
-1m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).
Key people
Armand Balboni
Chairman of the Board · since 2022
Don Cilla
President, Chief Executive Officer, Director · since 2022
Kenneth Howling
Acting Chief Financial Officer · since 2021
Arthur Baran
Director - New Product Development · since 2024
Carl Gelhaus
Director - Non-Clinical Research · since 2024
Gary Nabors
Chief Development Officer · since 2023
Brian Bloom
Independent Director · since 2023
Juergen Froehlich
Independent Director · since 2020
Independent Director · since 2023
Lead Independent Director · since 2023
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||